EMA Authorised: Givlaari (Givosiran) — Alnylam Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Givlaari (givosiran) for treatment of acute hepatic porphyrias, with orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Porphyrias

Drugs mentioned

• GIVLAARI (Givosiran)

Snippet

Status: Authorised. Therapeutic area: Porphyrias, Hepatic. MAH: Alnylam Netherlands B.V.. Decision date: 08/05/2025. Orphan medicine